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Simple Summary: The pathological role/s of the HERC family members has recently been initiated
to be explored in few solid tumors and the assessment of their transcript amount reveals that they
might act as effective prognostic factors. However, evidence concerning the non-solid tumors, and
especially myeloid related neoplasms, is currently lacking. In the present article for the first time
we provide original data for a clear and well-defined association between the gene expression level
of a giant HERC E3 ubiquitin ligase family member, HERC1, and some myeloid related disorders,
namely Acute Myeloid Leukemia, Myeloproliferative neoplasms and Chronic Myeloid Leukemia.
Furthermore, our findings unveil that the HERC1 protein physically interacts, likely forming a very
large supramolecular complex, and it is a putative BCR-ABL1 tyrosine kinase substrate. We hope
that this work will contribute to the advance of our understanding of the roles played by the giant
HERCs in myeloid related neoplasms.
Abstract: HERC E3 subfamily members are parts of the E3 ubiquitin ligases and key players for a
wide range of cellular functions. Though the involvement of the Ubiquitin Proteasome System in
blood disorders has been broadly studied, so far the role of large HERCs in this context remains
unexplored. In the present study we examined the expression of the large HECT E3 Ubiquitin
Ligase, HERC1, in blood disorders. Our findings revealed that HERC1 gene expression was severely
downregulated both in acute and in chronic myelogenous leukemia at diagnosis, while it is restored
after complete remission achievement. Instead, in Philadelphia the negative myeloproliferative
neoplasm HERC1 level was peculiarly controlled, being very low in Primary Myelofibrosis and
significantly upregulated in those Essential Thrombocytemia specimens harboring the mutation in
the calreticulin gene. Remarkably, in CML cells HERC1 mRNA level was associated with the BCR-
ABL1 kinase activity and the HERC1 protein physically interacted with BCR-ABL1. Furthermore, we
found that HERC1 was directly tyrosine phosphorylated by the ABL kinase. Overall and for the first
time, we provide original evidence on the potential tumor-suppressing or -promoting properties,
depending on the context, of HERC1 in myeloid related blood disorders.
Keywords: E3 ubiquitin ligases; ubiquitin proteasome system; myeloid neoplasms; Bcr-Abl1; HERC1;
gene expression; protein–protein interaction
1. Introduction
The function and activity of almost every cellular protein can be modulated by post-
translational modifications (PTMs) [1]. In particular, ubiquitination has emerged as one
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of the most conserved eukaryotic PTMs from yeast to human [2]. The ubiquitination is
a reversible and energy-dependent enzymatic process by which the ubiquitin is either
covalently linked to substrate proteins or alternatively can form free polyubiquitin chains.
The ubiquitination process requires three classes of enzymes, namely ubiquitin activating
(E1), ubiquitin conjugating (E2) and ubiquitin ligase (E3). The ubiquitin ligases are the
terminal enzymes transferring the ubiquitin to the e-amino group of a lysine residue on
the substrate or the amino-terminus of a polypeptide [3]. The E3 ligases often function
as multi-subunit complexes determining the substrate specificity [4]. In humans, the E3
ligase family comprises more than 600 members classified into three sub-families, based
on their structural and catalytic features, named RING (Really Interesting New Gene),
HECT (Homologous to the E6AP Carboxyl Terminus) and RBR (Ring Between Ring). The
HECT and RBR catalyse the ubiquitin transfer to the substrate by forming an E3-ubiquitin
thioester intermediate while RING members do not possess direct catalytic activity but rely
on the enzymatic activity of E2 to ubiquitinate the substrate [5].
The E3 ubiquitin ligases regulate many biological processes through timely ubiq-
uitination and degradation of many cellular proteins responsible for gene transcrip-
tion/repression, receptor endocytosis, intracellular trafficking, signal transduction, cell
cycle progression, DNA damage recognition and repair, autophagic clearance, differen-
tiation and apoptosis [6,7]. For these reasons, dysregulation of E3 ligases often leads to
the development of several forms of diseases such as central nervous system disorders,
inflammation, metabolic dysfunctions and several cancers [8,9] including hematologic
malignancies [10]. Remarkably, several ubiquitin ligases are mutated, overexpressed or
deleted in the hematologic malignancies, contributing to the pathogenesis of the diseases
through accumulation, or excessive degradation, of their substrates that may in turn acquire
critical functions during the hematopoietic cell growth and differentiation [10]. Deletions
within the locus of the large HECT E3 ubiquitin ligase HERC1 have been observed in
acute lymphoblastic leukemia (ALL) and have been associated to an increased resistance
to thiopurine antileukemic agents due to the control that HERC1 exerts on the stability
of the DNA mismatch repair enzyme MSH2 [11]. In addition, HERC1 point mutations
were recurrently found in few leukemias such as T-ALL [12], AML [13] and T-cell pro-
lymphocytic leukemia [14]. Eventually, a very rare and atypical HERC1-PML transcript
fusion mRNA was reported in acute promyelocytic leukemia [15]. Besides these reports,
in which the HERC1 mutational status has been associated with different leukemia, the
cellular functions of this protein in leukemia cells have been scarcely investigated. Thanks
to the efforts made by the Human Protein Atlas Project (proteinatlas.org) it has emerged
that the differential gene expression of HERC1 members might act as prognostic factor in
few solid tumours.
Indeed, recent findings indicate that HERC1 finely controls the ERK signaling by
regulating the c-Raf stability. HERC1 knockdown rises p38 activity by increasing the
levels of MKK3, an MAPKK, in a manner dependent on C-RAF [16]. Additionally, we
lately identified a large Dictyostelium HECT member (HectPH1), exhibiting many structural
similarities with the mammalian HERC1, as a suppressor of the mTORC2-PKB/AKT
signaling axis [17].
Hence, in the present study we sought to explore the role of HERC1 in myeloid blood
related disorders, to assess its potential role in the leukemogenesis process. Our find-
ings revealed that HERC1 gene expression was severely down-regulated both in acute
and in chronic myelogenous leukemia while it is peculiarly modulated in the myelo-
proliferative neoplasms, suggesting that in myeloid malignancies HERC1 display either
tumor-suppressing and -promoting properties depending on the context. Remarkably, in
CML cells the HERC1 transcript amount is associated to the BCR-ABL1 kinase activity
and HERC1 protein interacted with BCR-ABL1. Eventually, we showed that HERC1 is
tyrosine phosphorylated by the Abl kinase. Overall and for the first time, we provide
original evidence on the potential role of HERC1 in myeloid related blood disorders.
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2. Results
2.1. HERC1 Gene Expression Is Aberrantly Regulated in Myeloid Related Disorders
and Leukemias
Despite the mutational status of the genes, encoding for the large HERCs has been
scrutinized in different myeloid and lymphoid blood tumors [11,12,14], but their expression
levels in normal Bone Marrow (BM) and Peripheral Blood (PB) from healthy subjects has
never been assessed. Hence, initially we determined the HERC1 gene expression by 2−∆∆ct
methods in a cohort of healthy subjects by comparing its mRNA abundance in PB and BM
specimens. Interestingly, PB and BM displayed different levels of HERC1 mRNA, with the
amount in PB being significantly higher than in BM (Figure S1). Indeed, PB showed values
that were approximately twice those found in BM (PB median = 4.01 vs BM median = 2.20)
(Figure 1, red and dark red dots, respectively). Since our interest was related to myeloid
related disorders, we then assessed the HERC1 gene expression in a panel of myeloid
malignancies including AML (n = 97), MPNs (n = 78.) and CML (n = 72).
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Figure 1. The ERC1 gene expression is differently regulated in bone arrow (B ) and peripheral
blood (PB) and it is dysregulated in haematological malignancies. HERC1 transcript was assayed in
healthy donors including both PB (red dots) and BM (dark red dots), and in a panel of myeloid related
disorders at diagnosis, namely Chronic Myeloid Leukemia (CML) (PB = 37, BM = 35), Acute Myeloid
Leukemia (AML) (PB = 17, BM = 80), MyeloProliferative Neoplasms (MPNs) (PB = 75) by RT-qPCR.
The HERC1 mRNA quantity was expressed as 2−∆∆Ct after normalization against GUSB. HERC1
gene expression was significantly downregulated in newly diagnose CML and AML, with edian
values of 0.9 and 1 r spectively, when compared to healthy specimens (median = 4.01). In MPNs the
HERC1 expre sion fluctuated from 0.4 to 12.65 with a median value of 3.3 and thus not significantly
different from healthy subjects. p-values were calculated on the differences in HERC1 gene expression
observed between patients and the healthy control specimens. * p < 0.05, **** p < 0.0001.
When compared to the pool of PB and BM healthy specimens, the HERC1 gene expres-
sion was sharply downregulated at diagnosis both in acute (median value approximately
of 1.0) and in chronic myeloid (median value approximately 0.93) leukemia. Differently,
in MPNs specimens we observed that the HERC1 gene expression level did not signifi-
cantly differ from that of the healthy subjects, albeit the values appeared rather disperse
within a window ranging from 0.40 to 12.65 with a median value of 3.33 (Figure 1). On
the whole, HERC1 gene expression is differentially regulated in PB and in BM, markedly
downregulated both in AML and CML and expressed with a rather scattered pattern in the
MPNs group.
2.2. Newly Diagnosed AML Display HERC1 Down-Regulation Independently from the
Genetic Alterations
The AML is the most common type of leukemia in adults and is characterized by a high
degree of genetic heterogeneity, including inactivation of oncosuppressors [18]. Hence, it is
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among the most challenging myeloid neoplasms to be treated [19]. We examined the gene
expression of HERC1 in this type of leukemia according to the most common cytogenetic
and genetic alterations. The HERC1 expression level was assessed in newly diagnosed
AML (80 were BM and 17 PB specimens). Interestingly, both the BM and the PB specimens
collected from newly diagnosed AML patients exhibited comparable HERC1 transcript
amounts (BM median = 0.97 vs PB median = 1.12), revealing that the expression levels were
distinctly decreased in both BM and PB patient’s samples (p < 0.0001) (Figure 2A).
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hematopoietic stem-cell disorders characterized by an abnormal proliferation of one or 
more terminal myeloid cells. They include Essential Thrombocythemia (ET), Polycythe-
mia Vera (PV) and Primary Myelofibrosis (PMF). The PV and ET are chronic diseases 
associated with a long life expectancy, while PMF is a more aggressive disease charac-
Figure 2. The HERC1 transcript is severely downmodulated in acute myeloid leukemia independently from genetic
alteration. (A) HERC1 level is significantly downregulated in both PB (n = 17) and BM (n = 80) specimens derived from
AML at diagnosis. (B) The stratification of the AML samples according to the different cytogenetic categories and to the
most common genetic variants displayed that the HERC1 transcript downregulation is a common feature shared by almost
all the different groups with the exception of the IDH2 mutated cohort, in which its gene expression is comparable to that of
the controls. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
Since AML displays quite a broad genetic diversity we stratified the BM specimens
collected at diagnosis according to the most common cytogenetic and genetic variants,
being the resulting groups comparatively age-matched (Supplementary Table S4). By
comparing the HERC1 transcript among the different categories we did not observe any
ajor difference (Figure 2B) besides the IDH2 mutated specimens, in which the HERC1
gene expression was significantly higher when compared to all the other AML subgroups
(ANOVA, p = 0.03), displaying a median level (1.9) similar to that of the healthy donors
(p = 0.27).
These results indicated that in AML patients the HERC1 gene expression level was
significantly lower at diagnosis and not associated with any of the different cytoge-
netic/genetic group with the interesting exception of the five AML patients harboring
the IDH2 R140Q mutation which displayed HERC1 levels indistinguishable from the
control group.
2.3. MPNs Display a Peculiar Pattern of HERC1 mRNA Abundance
Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) are hemato-
poietic stem-cell disorders characterized by an abnormal proliferation of one or more
terminal myeloid cells. They include Essential Thrombocythemia (ET), Polycythemia Vera
(PV) and Primary Myelofibrosis (PMF). The PV and ET are chronic diseases associated with
a long life expectancy, while PMF is a more aggressive disease characterized by harsher
symptoms. As opposed to the Philadendia-positive myeloid neoplasm, namely CML, the
Cancers 2021, 13, 341 5 of 14
MPNs are characterized by different somatic genetic mutations involving JAK2, Calreticulin
(CALR) and the thrombopoietin receptor (MPL) encoding genes [20].
The expression pattern of HERC1 in MPNs appeared rather scattered and different in
each category. Among the three different MPNs, the PB samples from ET patients (n = 39)
were those displaying the most variable HERC1 gene expression levels (ranging from 1.4 to
12.6). Interestingly, while either the ET specimens harboring the JAK2V617F mutation or
those non-mutated displayed HERC1 levels similar to the controls, those mutated for CALR
exhibited significantly higher HERC1 mRNA level (median 7.3) (Figure 3A). Conversely,
the non-mutated PMF patients (n = 11) displayed a very low amount of HERC1 transcript
(median = 0.8) (Figure 3B) with values very similar to those previously observed in AML
and CML specimens. Worthy of note, the PMF JAK2V617F mutated patients showed
a slightly, but significantly (p = 0.0001) higher level of HERC1 mRNA (median = 2.3)
when compared to the non-mutated group. Eventually, specimens from Jak2 V617F PV
patients showed a moderate, though significant, lowering in HERC1 gene expression level
(Figure 3C).
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after the molecular remission (BCR-ABL1IS ≤ 0.1%) the level of the HERC1 transcript 
sharply increased reaching values (median = 3.5) comparable to those observed in the 
control subjects (median = 3.5 and 3.1 for PB and BM, respectively) (Figure 4A). Ulti-
mately, when patients relapsed again a reduction in HERC1 gene expression occurred. 
Due to the very large size of the HERC1 protein, in human primary cells we encountered 
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levels in CML specimens collected at different clinical stages (diagnosis, remission and 
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Figure 3. HERC1 mRNA is differentially and peculiarly expressed in MPNs patients. On the whole,
the expression pattern of HERC1 in MPNs appeared to be rather scattere and variable. Among
MPNs, when compared to the healthy subjects, the CALR mutated Essential Thrombocythemia (ET)
specimens (A) displayed a significantly higher amount of HERC1 transcript, (p ≤ 0.0001). On the
contrary, the JAK2 mutated, and non-mutated, specimens showed levels comparable to the control
counterpart. (B) Differently, the Primary Myelofibrosis (PMF) patients displayed a rather steep
downregulation of HERC1 gene expression. However, the JAK2V617F mutated samples showed
higher HERC1 levels in comparison to the mutation free cohort. (C) In Polycythemia Vera (PV)
patients the HERC1 mRNA level was slightly, but significantly, lower than that of the healthy subjects
(** p < 0.01, *** p < 0.001, **** p < 0.0001).
2.4. The HERC1 Expression Is Sensitive to the Bcr-Abl1 Tyrosine Kinase Activity
By measuring the transcript level of HERC1 in CML patients at diagnosis we noticed
that this was decreased in both PB (median = 1.03) and BM (median = 0.66) specimens.
We then asked whether HERC1 expression might be affected by the different CML clinical
stages, including diagnosis, remission and relapse. Our analysis unveiled that after the
molecular remission (BCR-ABL1IS ≤ 0.1%) the level of the HERC1 transcript sharply
increased reaching values (median = 3.5) comparable to those observed in the control
subjects (median = 3.5 and 3.1 for PB and BM, respectively) (Figure 4A). Ultimately, when
patients relapsed again a reduction in HERC1 gene expression occurred. Due to the
very large size of the HERC1 protein, in human primary cells we encountered technical
difficulties in blotting it. Hence, we decided to determine the HERC1 protein levels in
CML specimens collected at different clinical stages (diagnosis, remission and relapse)
by immunofluorescence. Consistently with gene expression results, the HERC1 protein
amount was low at diagnosis but increased during remission and declined again when
patients relapsed (Figure 4B).
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Figure 4. HERC1 gene expression is differently regulated in CML patients during the evolution of the disease. (A) HERC1
gene was differentially expressed during the different CML phases being severely down-regulated at diagnosis, both in BM
and PB CML specimens, increased at remission and declined again at the onset of relapse. (B) Similarly to the mRNA, in
primary CML cells the HERC1 protein amount was barely detectable at diagnosis and at the relapse onset. On the contrary,
at remission the protein level was comparable to that of healthy control. Immunofluorescence was performed on cytospun
cells by using specific rabbit polyclonal anti HERC1 antibody. DAPI staining (blue) indicated the cell’s nuclei. The green
signal corresponds to the HERC1 protein. * p < 0.05, **** p < 0.0001.
In CML patients, the remission is usually achieved in response to tyrosine kinase
inhibitors (e.g., Imatinib®) monotherapy. Therefore, we assessed the HERC1 expression
at both mRNA and protein levels in primary CML cells treated for 48 h with Imatinib.
Interestingly, Imatinib-dependent BCR-ABL1 inhibition enhanced, though not significantly,
the HERC1 transcript amount (Figure 5A).
These results prompted us to ascertain whether the BCR-ABL1 tyrosine kinase might
affect the HERC1 expression. Hence, we transfected the HEK-293T cell line with the p210
BCR_ABL1 overexpressing plasmid. Interestingly, the BCR-ABL1 overexpression led to
a significant lowering of HERC1 both at transcript and protein level (Figure 5B–D) in
agreement with the findings in CML specimens at diagnosis.
2.5. HERC1 Is a Novel Binding Partner and a Substrate of BCR-ABL1
Besides the HECT and the RLD domains, and despite their very large size, the HERC
E3 Ub-ligases harbor only few recognizable structural regions [21]. Noticeably, many
somatic mutations associated with different tumors fall within unknown structural con-
strained amino acid stretches [22]. In the last years quite a few efforts have been made
to identify HERCs interacting partners with the aim of gaining insight of the cellular
functions of these proteins [23]. While currently the HERC2 accounts for dozens of binding
partners [24], no more than a bunch have been experimentally ascertained for HERC1.
By analyzing and comparing the HERC1 and BCR-ABL1 subcellular localization in
K-562 cells, we observed that both proteins displayed a diffuse pattern and mostly they
co-localized (Figure 6A). It is noteworthy that HERC1 showed a more spotted pattern,
when compared to BCR-ABL1, with “speckle-like” structures mainly dispersed within the
cytoplasmic compartment. These observations prompted us to investigate whether the two
proteins might also interact.
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Figure 5. HERC1 RNA and protei amounts are regulated by the Bcr-Abl1 tyrosine kinase activity.
(A) Primary bone marrow derived from leukemic cells of newly diagnosed CML patients (n = 5) dis-
played a modest increase i HERC1 mRNA quantity af r in vitro Imatinib (2.5 µM) treatment. (B,C)
HEK-293T transiently and exogenously expressing the constitutively active p210 BCR-ABL1 tyrosine
kinase exhibited a severe down-modulation of HERC1 protein examined by immunofluorescence
(B) and Western Blot (C). DAPI staining (blue) indicated the cells nuclei while the green signal was
corresponding to HERC1 protein. (D) HERC1 mRNA level was significantly reduced in HEK-293T
overexpressing the BCR-ABL1 (** p < 0.01).
Interestingly, the HERC1 turns out to be even tyrosine phosphorilated (Figure 6B).
Since BCR-ABL1 displays constitutive tyrosine kinase activity and phosphorylates a
very broad spectrum of diff rent effectors, we next asked whether the HERC1 tyro-
sine phosphorylation status might be affected by BCR-ABL1 itself. Hence, we deter-
mined the HERC1 tyrosine phosphorylation status in K562 cells. Immunopr cipitation
of K562 lysates with an anti-phosphotyrosine specific antibody and the subsequent im-
munoblotting with anti-HERC1 antibody unveiled that HERC1 is one among many pro-
teins heavily phosphor lated in this CML cell line (Figure S2A). An in-sil co search
(www.cbs.dtu.dk/services/NetPhos) revealed that HERC1 protein harbors several pu-
tative tyrosine phosphorylation sites and at least three of them (Y905, Y3867 and Y4452)
appeared to be bona fide BCR-ABL1 phosphorylation consensus motif [25]. Altogether,
these bodies of evidence suggested that BCR-ABL1 may directly phosphorylate HERC1.
To validate this surmise, we performed an “in-vitro” kinase assay by mixing the purified
c-ABL1 kinase with the putative HERC1 substrate. c-ABL1 directly phosphorylated HERC1
on tyrosine residues, and this phosphorylation was significantly inhibited by treatment
with Imatinib (Figure 6C,D). On the whole these findings indicate that HERC1 is a novel
binding partner and a substrate of BCR-ABL1.
To this purpose, we attempted to pull-down HERC1, in K562 Ph-positive cells, by
co-immunoprecipitation experiment using as bait BCR-ABL. As revealed by the intense
and sharp HERC1 Western Blot band, obtained after BCR-ABL1 immunoprecipitation, the
two proteins not only colocalized but they also interacted with each other (Figure 6B).
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Figure 6. HERC1 is a novel interactor and a potential substrate of Bcr-Abl1. (A) The subcellular
localization of either the HERC1 or Bcr-Abl1 (p210) proteins were assessed by staining cytospun K562
cells with anti-HERC1 and anti-Bcr specific antibodies. The immunofluorescence assay revealed that
the localization of the two proteins was mostly restricted to the cytoplasmic compartment and they co-
localiz d. (B) In K562 cells BCR-ABL1 and HERC1 proteins f rm a complex. The immunoprecipitated
BCR-ABL1 was employed to pull-down HERC1 from K562 total cell lysate. The presence of HERC1
in the immunopr ipi ated sam le was det rmi ed by immunoblotti g the membrane with HERC1
antibody (upper panel). Subsequently probing with a tyrosine phospho-specific antibody proved
the phosph ylat HERC1 status. Vinculin was used s loading control (lower panel). (C) In vitro
kinase assay with purified c-ABL and HERC1 substrate, obtained after HERC1 immunoprecipitation
on 293T, performed in the absence or presence of 5 µM Imatinib treatment for 30 min. (D) The effect
of the Imatinib showed in (C) was measured quantitatively using the ImageJ software. The bands
i tensity, corresponding to HERC1-P-Tyr protein, were quantified and normalized to the amount of
HERC1 protein signal for each lane (the max value was set at 1). Normalized arbitrary units of three
different experiments with SD are shown in the bar graphs. * p < 0.05.
3. Discussion
To overcome stresses and to properly balance the entire proteome, every eukaryotic cell
relies on the ubiquitin prot asome system (UPS). Damaged, or malfunctioning, proteins are
ubiquitin tagged and then degraded by the 26S proteasome. However, the ubiquitination
process is not exclusively engaged under stress conditions. Indeed, ubiquitin moieties
can serve as a docking site for protein–protein interaction. Eventually, as important as
the ubiquitin conjugates the cell survival and proliferation rely also on the free ubiquitin
chains and the free ubiquitin pool [26]. Alterations in the UPS are often associated with
severe diseases and numerous E3 Ubiquitin ligases are aberrantly regulated in different
cancers [27,28].
Despite the HECT sub-family members representing a small proportion of the E3
ubiquitin ligase superfamily many of them have been found to be either aberrantly reg-
ulated or mutated in several tumors [8,9]. Among HECT proteins, the HERC subfamily
comprises two giant members, HERC1 and HERC2. Mutations in either genes have
been reported in some kinds of lymphoid leukemia (e.g., acute lymphoblastic and pro-
lymphocytic leukemia) and solid tumors (e.g., breast cancers, non-melanoma skin and
gastric carcinoma) [22].
However, currently, specific inquiries aiming to assess the potential role of the giant
HERCs in myeloid related neoplasia are lacking. We initially started by appraising the
HERC1 transcript amount in healthy subjects and by comparing its levels between the PB
and the BM. Afterwards, we moved to a panel of myeloid related disorders including AML,
MPNs and CML. Interestingly, our findings revealed that in healthy control specimens the
HERC1 is differentially transcribed when comparing PB and BM, displaying significantly
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lower levels in the BM (Figure S1). Furthermore, by determining the quantitative expres-
sion of the HERC1 gene in a panel of myeloid related disorders we found a steep decline
in those samples collected from patients with newly diagnosed AML, CML and PMF
(Figure 1). Noteworthy, alike HERC1, the ARIH2 gene that encodes for an RBR member
named TRIAD1 is expressed at a very low level in BM but it steeply rises in PB. Though the
ARIH2 transcript amount in acute promyelocytic cell line (NB4) is low [29], suggesting a
similar expression pattern in acute myeloid leukemia patients, an inclusive study aiming to
evaluate its expression level in a cohort of patients affected by different myeloid disorders is
lacking. On the contrary, the molecular mechanisms controlling the ARIH2 gene expression,
and its cellular role in regulating the hematopoiesis, have been comprehensively scruti-
nized in cell lines and murine models [30,31]. Overall, these studies unveiled that TRIAD1
inhibits the clonogenic growth of primary myeloid progenitor cells but it is required to
induce both granulocytic and monocytic differentiation thus making it a player in myeloid
cell differentiation [29]. Based on our findings we cannot exclude that, similarly to TRIAD1,
HERC1 might be involved in blood cell differentiation thus contributing to the proper
hematopoiesis. Future investigations, aiming to functionally explore the functional role
of HERC1 in blood cells, are required. Akin to HERC1, the WWP1 is a member of the
HECT family and its clinical relevance in AML has been assessed. Contrarily to HERC1
the WWP1 expression is significantly upregulated in AML specimens. Nonetheless, as
observed for HERC1 the WWP1 transcript levels are regulated independently from the
different cytogenetic categories and genetic variants [32]. Remarkably, we additionally
perceived that those patients harboring the IDH2-R140Q mutation showed higher HERC1
transcript levels when compared to all the other cytogenetic categories and genetic variants
we screened (Figure 2B). The mutated IDH2 enzyme is characterized by a peculiar neomor-
phic activity resultant in the synthesis of a novel oncometabolite, the 2-hydroxyglutarate,
which in turn inhibits the α-ketoglutarate-dependent epigenetic regulators (e.g., histone
demethylase TETs). As a consequence, the genomic DNA results hypermethylated thus
contributing to profoundly impair the cellular differentiation [18,33]. Our results advise
to argue that, likely, the IDH2-R140Q-dependent genomic DNA hypermethylation leads
to the transcriptional repression of an, by now, unknown transcriptional repressor and
thus maintains unaltered the HERC1 mRNA levels. Further research will be required to
ascertain this hypothesis.
Conversely from PMF, the other two MPNs showed higher HERC1 levels that were
either quite similar to those of the healthy subjects, as it occurred for PV, or even higher as it
was in the case of the CALR mutated ET samples (Figure 3A). Unambiguously, our findings
indicate that in MPNs the HERC1 transcript inversely correlates with the severity of the
disease, the PMF specimens being those with the lowest level of HERC1, but not with the
JAK2 mutational status in PV and ET. Furthermore, among MPNs the CALR mutated ET
patients, displaying a favorable prognosis, exhibited the highest HERC1 gene expression
level, with a median value of 7.3 that was significantly higher than that of healthy controls.
The recurrent CALR somatic mutations cause a +1 frameshift in the reading frame leading
to mutant specific CALR carboxyl-terminus that lacks the Endoplasmic Reticulum (ER)-
retention signal (KDEL). Calreticulin is a lectin chaperone that, alongside GRP78 and
calnexin, promotes and facilitates the proper folding and maturation of the ER luminal
proteins. Damaged or improperly folded proteins usually escape the calreticulin cycle
and enter the ER Associated Degradation (ERAD). Otherwise proteins can continue their
journey and when required move to Golgi Apparatus. Though CALR deficient cells exhibit
accumulation of misfolded proteins, the ER structure remains unaltered. However, a
significant increase in ubiquitin-proteasome activity has been detected as a result of a
compensatory mechanism for cell survival [34]. Furthermore, it is well known that ER
stress leads to activation of both the Unfolded Protein response (UPR) and autophagy
processes that it turns out tightly depend on the ubiquitination process. A transcriptomic
analysis carried out on a colon cancer cell line treated with ER stressors (e.g., brefeldin A
and tunicamycin) revealed an up-regulation of a large group of autophagy related genes,
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including HERC1 [35]. These data, together with the HERC1 subcellular localization in
inner membranes (e.g., Golgi Apparatus) suggest that the Ubiquitin Proteasome System
(UPS) might be a novel potential, and by now uninvestigated, player in the pathogenesis of
the ET CALR mutation, and could contribute to the clonal advantage in hematopoietic cells
by downregulating pro-apoptotic, or pro-differentiating, signaling processes. Furthermore,
among the MPNs group those patients expressing either the highest, or the lowest, HERC1
transcript levels define two novel subsets that overlap with ET CALR mutated and PMF
groups thus leading to wonder whether the HERC1 transcript levels might represent a
novel additional diagnostic marker along with the ones currently available.
Differently from its closest relatives, namely ET, PV and PMF, the CML is characterized
by a single genetic alteration giving rise to a constitutively active tyrosine kinase, the BCR-
ABL1 fusion protein. This peculiar molecular landmark confers unique properties to be
feasibly investigated from the very basic biological point of view by simply overexpressing,
or pharmacologically inhibiting (e.g. Imatinib), the BCR-ABL1 protein. Our findings
indicate that upon effective Imatinib treatment the HERC1 mRNA levels raised sharply
to levels similar to that of the control specimens but decreased again when the patients
relapsed (Figure 4A). Consistently, cells overexpressing Bcr-Abl1 displayed lower HERC1
transcript when compared to the control (Figure 5B–D). Though the genotype is different,
the newly diagnosed AML, PMF and CML displayed low amounts of HERC1 transcript
when compared to the healthy control. Nonetheless, Bcr-Abl1 appears to trigger a decline in
HERC1 gene expression. Hence, it is conceivable to hypothesize that: (a) in AML, PMF and
CML, HERC1 might act as an oncosuppressor [36] and (b) though genotypically different
all these myeloid disorders share a common HERC1 transcriptional repressor mechanism
that in CML it is positively regulated by BCR-ABL1.
The different structural motifs characterizing the BCR-ABL1 fusion protein allow
it to interact with dozens of binding partners [37]. Amongst them there are also few
UPS components, comprising E3 Ubiquitin-ligases and deubiquitylating enzymes (e.g.,
Cbl, USP1) [38,39], that are fundamental to controlling the BCR-ABL1 stability and as a
consequence its oncogenic potential. Our data indicate that HERC1 represents both a novel
BCR-ABL1 interacting partner and a substrate. However, the functional meaning of the
interaction and tyrosine phosphorylation remain presently to be ascertained. Currently, it
cannot be excluded that HERC1 might act as BCR-ABL1 negative regulator and the tyrosine
phosphorylation might control its enzymatic activity. Consistently, the enzymatic activity
of Nedd4, a HECT E3 Ubiquitin-ligase member, is tightly regulated by the phosphorylation
of a few tyrosine residues [40].
Additional studies are needed to dissect the functional relevance of the HERC1 aber-
rant expression in myeloid related disorders. Indeed, though our data suggest that HERC1
plausibly plays a role as oncosuppressor in the majority of myeloid malignancies (e.g.,
AML, CML and PMF) by now we cannot rule out that in those ET calreticulin mutated it
might display tumor-promoting properties, thus exerting different properties depending
on the context. Determining the most relevant HERC1 substrates might represent a useful
hint for novel druggable molecular targets.
4. Materials and Methods
4.1. Patients and Cell Lines
After written informed consent, specimens from CML, AML and MPNs were collected.
In addition, peripheral blood (PB) and bone marrow (BM) specimens were also collected
from healthy donors. Among CML samples, 37 were PB and 35 BM (Supplementary
Table S1), among AML specimens, 80 were BM and 17 were PB (Supplementary Table S2)
while MPNs specimens were PB (Supplementary Table S3). The K-562 and HEK-293T
cell lines were cultured in complete RPMI-1640 and Dulbecco’s modified Eagle’s medium,
respectively. Primary CML cells derived from patients’ bone marrow were cultured in
ISCOVE’s medium, supplemented with heat inactivated 20% foetal bovine serum.
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4.2. Quantitative Real-Time PCR
Total RNA was extracted, reverse transcribed and then transcript quantification anal-
ysis performed as described elsewhere [41]. For HERC1 mRNA quantification, specific
assays (assay ID for GUSB Hs00939627_m1, and Hs01032486_m1 for HERC1-Applied
Biosystems, Thermo Fisher Scientific, Massachusetts, MA, USA) were used. The HERC1 Ct
values obtained by RT-qPCR were normalized with respect to the Ct counterparts of GUSB
and expressed as 2−∆∆Ct. A universal human references RNA (Stratagene, San Diego, CA,
USA) was used to calibrate the assay.
4.3. Cell Lysis and Immunoprecipitation
For total protein extraction, cells were washed with ice cold phosphate-buffered saline
(PBS), and lysed as described [42]. For immunoprecipitation (IP) 1500 µg of total proteins
were used. The protein lysates were incubated overnight at 4 ◦C with 2 µg of appropriate
antibody and subsequently for 45 min at 4 ◦C with Protein A/G Sepharose (SC-2001#J1510,
Santa Cruz Biotechnology). The immune-complex Sepharose beads were then washed with
a lysis buffer and absorbed proteins were eluted in the SDS-sample buffer.
4.4. Western Blotting
One hundred micrograms (100 µg) of total protein were loaded and run onto 4%–
14% gradient precasted gel (CriterionTM TGX Stain-FreeTM, Bio-Rad, Hercules, CA, USA)
electrophoresis and transferred to PVDF (Bio-Rad, Hercules, CA, USA) membranes as
described elsewhere [42]. Blots were blocked in TBS plus 5% non-fatty acid milk and
decorated with appropriate primary antibodies (HERC1 #A301-904A, Bethyl Laboratories
Inc., Montgomery, TX, USA; β-Actin, sc-47778, phospho-Tyr, sc-7020, c-Abl, sc-23 and
BCR, sc-20707, Santa Cruz Biotechnology, Dallas, Texas, USA; Vinculin MA5-11690, Invitro-
gen, Carlsbad, CA, USA). Membranes were then washed and incubated with appropriate
peroxidase-linked secondary antibody (Santa Cruz Biotechnology, Dallas, TX, USA). Spe-
cific binding was detected using an enhanced chemiluminescence system (Clarity Western
ECL Substrate #170-5061, Bio-Rad, Hercules, CA, USA).
4.5. Immunofluorescence Staining
Cytospins were prepared using K562, BM and PB cells from CML patients, while HEK-
293T cells were grown on coverslips [43]. Cells were fixed with 4% PFA, permeabilized with
0.1% TritonX100 and blocked with a blocking buffer (10% foetal bovine serum, 5% BSA,
1% fish gelatin). Afterwards, cells were washed with 1X-PBS and then incubated with anti-
HERC1 antibody. Protein detection was obtained by incubation with a secondary antibody
(A11011 Alexa Fluor 568 IgG, Invitrogen). Nuclear staining was performed with DAPI.
Images were captured with a confocal microscope equipped with a 63x oil immersion
objective (LSM 5110; Carl Zeiss. MicroImaging Inc., Oberkochen, Germany).
4.6. Plasmids and Transfection
The p210 Bcr-Abl1 overexpressing plasmid [44] was used to transiently transfect
HEK-293T cells by X-treme GeneHP (Roche, Basel, Switzerland) according to the manufac-
turer’s instructions.
4.7. In-Vitro Kinase Assay
The kinase assay was performed with immunoprecipitated HERC1 substrate and
purified full-length c-ABL1 (Invitrogen, #P3049) as described elsewhere [44]. Briefly, the
HEK-293T cells were lysed in CHAPS buffer (10 mM Tris–HCl pH 7.5, 100 mM NaCl,
0.3% CHAPS, 50 mM NaF, 0.5 mM EDTA, 1mM Na3VO4, 1mM PMSF, 2 µg/mL leupeptin,
5 µg/mL aprotinin, 2 µg/mL pepstatin), and endogenous HERC1 was immunoprecip-
itated as mentioned above in Section 4.3. Purified full-length ABL (Invitrogen, #P3049)
and immunoprecipitated endogenous HERC1 were resuspended in kinase buffer (50 mM
HEPES, 150 mM NaCl, 1 mM MgCl2, 1 mM MnCl2, 10 mM NaF, 1 mM NaVO3, 5% glyc-
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erol, 1% NP-40, 1 mM DTT, 1 mM PMSF) and 10 mM ATP (Sigma). After 30 min at
37 ◦C, reaction was stopped by the addition of SDS–PAGE buffer, followed by boiling
for 10 min at 100 ◦C. Protein samples were separated on 4%-14% gradient precasted gel
(CriterionTM TGX Stain-FreeTM, Bio-Rad, Hercules, CA, USA) electrophoresis and trans-
ferred to PVDF (Bio-Rad, Hercules, CA, USA) membranes, and incubated with anti-HERC1
and anti-phosphotyrosine antibodies. Membranes were then washed and incubated with
appropriate peroxidase-linked secondary antibody (Santa Cruz Biotechnology, Dallas,
Texas, USA). Specific binding was detected using an enhanced chemiluminescence system
(Clarity Western ECL Substrate #170-5061, Bio-Rad, Hercules, CA, USA).
4.8. Statistical Analysis
Graphs are presented with error bars representing standard error calculation. Paired
t-test or one-way ANOVA were used for non-parametric statistical analysis using GraphPad
Prism v5.0 (GraphPad Software, Inc., La Jolla, CA, USA). * p < 0.05, ** p < 0.01, *** p < 0.001,
**** p < 0.0001.
5. Conclusions
In conclusion, for the first time we assessed the expression levels of the gene encoding
for the giant Hect E3 Ubiquitin ligase, HERC1, in white blood cells and in a panel of
myeloid related disorders including AML, MPNs and CML. Though, in myeloid leukemia
and related neoplasms, the HERC1 transcript levels were mostly down-regulated, thus
likely acting as an oncosuppressor, we noticed that there are few remarkable exceptions
suggesting that its role is tightly context-dependent. The constitutively active BCR-ABL1
tyrosine kinase contributes significantly in lowering the HERC1 gene expression. Into the
bargain, the HERC1 protein represents a novel BCR-ABL1 interacting partner and substrate.
Taken together our findings potentially open up a critical issue for further studies to learn
more about HERC1 biology and its role in human diseases.
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